The area of research on probabilistic and randomized methods for analysis and design of uncertain systems is fairly recent and is focused both on algorithmic as well as theoretical developments.
The highest Integrilin dose group from the nonrandomized phase and the randomized patients were pooled for analysis and compared with placebo-treated patients.
Sixty-six of 87 randomized patients were evaluable for analysis.
The highest eptifibatide dose group from the nonrandomized phase and the randomized patients were pooled for analysis and compared with placebo-treated patients.
Consistent with CONSORT requirements for analysis of randomized controlled trials, we undertook statistical evaluation using "intention-to-treat" analysis, where outcomes were evaluated among all randomized practices, regardless of their uptake of CME interventions.
RESULTS: A total of 139 patients were randomized, of whom 100 were eligible for analysis.
To avoid a carry-over effect, only the first randomized cross-over period was considered for analysis.
We identified 332 relevant literatures via electronic searches, the overlap studies were excluded, and finally 19 studies on randomized controlled trials (RCTs) were left for analysis which involved 3148 patients in total (who were included in LAM therapy groups).
For example, in the study by Urban et al. [ 5], out of 88 randomized infants, only 57 (64.7%) were available for analysis; in the study by Barclay et al.[ 4], out of 111 randomized infants, only 56 (50%) were available for analysis.
Borm, G., Fransen, J. & Lemmens, W. A simple sample size formula for analysis of covariance in randomized clinical trials.
